← Retour à la une
États-Unis · Plateformes & données · The Motley Fool

Is Kimberly-Clark Stock a Buy Now That the Kenvue Acquisition Is Finalized?

Publié par The Motley Fool · États-Unis il y a 33 min
Is Kimberly-Clark Stock a Buy Now That the Kenvue Acquisition Is Finalized?
Is Kimberly-Clark Stock a Buy Now That the Kenvue Acquisition Is Finalized? · The Motley Fool

Résumé détaillé

Cost savings may be a bigger benefit of the Kenvue acquisition than revenue growth.

Kimberly-Clark (KMB +2.37%) closed its acquisition of Kenvue, a consumer health company spun off from Johnson & Johnson (JNJ +1.19%), on Nov. 2.

The deal was valued at $48.7 billion, and Kimberly-Clark expects Kenvue to offer $2.1 billion in merger-related savings and revenue gains. That sounds good, but management still has to prove Kenvue is a value driver rather than just an expensive acquisition.

Kimberly-Clark has brands found in homes across the world, including Kleenex, Huggies, and Cottonelle. Adding Kenvue's product portfolio to its lineup seems like a strong fit, as those are also items people generally don't think twice about reaching for when they need them. Kenvue's offerings include the brands Tylenol, Neutrogena, Listerine, and Band-Aid.

"This transaction brings together two iconic American companies to create a combined portfolio of complementary products, including 10 billion-dollar brands, that touch nearly half the global population through every stage of life," Kimberly-Clark said in a press release.

Interestingly enough, the main appeal of the deal may not be sales contributions. While Kimberly-Clark expects $2.1 billion in synergies (reinvesting $300 million), only $500 million of that is incremental profit expected to be obtained within the first four years after the acquisition closed.

The bulk of the acquisition's value lies in cost savings, which could be worth $1.9 billion and could be achieved within the first three years after the acquisition. Compared to those revenue assumptions, lower costs and higher margins will be easier to spot in quarterly reports.

Everything looks good on paper, but there's a difference between projections and execution. Kenvue was spun off from Johnson & Johnson in 2023, allowing the legacy brand to focus more on high-growth areas.

Kenvue may ultimately be a better fit for Kimberly-Clark's portfolio than for Johnson & Johnson's. But there's no guarantee that the synergies Kimberly-Clark expects will take shape.

Also…

Début de l'article, extrait de The Motley Fool. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur The Motley Fool Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)

À lire aussi